Second Half

TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update

Retrieved on: 
Monday, April 1, 2024
Oncology, Health, Medical Devices, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, HCPCS, Interest, Second Half, Patient, APC, Sale, Society, University, Bank statement, Investment, Therapy, Marketing, DCR, Webcast, Hepatocellular carcinoma, CMS, Abdominal ultrasonography, Vein, Disease, Opinion, Immunotherapy, Safety, Manuscript, Cholangiocarcinoma, Pancreas, PFS, FDA, Liver disease, HCC, OS, Uveal melanoma, MDSC, Growth, TACE, Commander, U.S. Pacific Fleet, Drug, MD Anderson Cancer Center, Data, Medicare, Liver, Pharmaceutical industry

TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced its financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.

Key Points: 
  • TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced its financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
  • This new code, HCPCS 9797, has been assigned to the Ambulatory Payment Classification (APC) 5194 – Level 4 Endovascular Procedures.
  • The Company is working diligently to evaluate the materiality of the errors to determine whether any corrections for the third quarter financial results are required and to complete the Company’s year-end 2023 financial statements.
  • Operating losses were $14.1 million and $54.2 million, respectively, for the fourth quarter and full year ended December 31, 2023.

Grindrod Shipping Holdings Ltd. Announces Unaudited Financial Results for the Second Half and Full Year Ended December 31, 2023

Retrieved on: 
Wednesday, February 28, 2024
Acquisition, Ship, TCE, Safety, Sale, Handymax, Second Half, GAAP, EGM, Depreciation, TMI, Cryptocurrency

Unaudited Results for the Full Years Ended December 31, 2023 and 2022

Key Points: 
  • Unaudited Results for the Full Years Ended December 31, 2023 and 2022
    Revenue was $387.1 million for the year ended December 31, 2023 and $460.5 million for year ended December 31, 2022.
  • Administrative expense was $32.7 million for the year ended December 31, 2023 and $48.1 million for the year ended December 31, 2022.
  • Interest income was $2.8 million for the year ended December 31, 2023 and $2.2 million for the year ended December 31, 2022.
  • Interest expense was $17.1 million for the year ended December 31, 2023 and $17.1 million for the year ended December 31, 2022.

Pyxus International, Inc. Reports Fiscal Year 2024 Second Quarter Results with Strong Top and Bottom Line Results

Retrieved on: 
Tuesday, November 14, 2023
Sale, EBITDA, Webcast, Pandemic, Reproduction, Heated tobacco product, Security (finance), Foreign Corrupt Practices Act, OTC Markets Group, Visibility, Policastro Bussentino, Annual report, Nationalization, Collection, Pyxus International, Risk, Exercise, Government, Second Half, Tobacco, Weather, Farmer, Table, GAAP, Adjustment, Geography, Death, Growth, Failure, Retail, Video game, Hamas

MORRISVILLE, N.C., Nov. 14, 2023 /PRNewswire/ -- Pyxus International, Inc. (OTC Pink: PYYX) ("Pyxus," the "Company," "we," or "our"), a global value-added agricultural company, today announced results for its fiscal quarter ended September 30, 2023.

Key Points: 
  • Pieter Sikkel, Pyxus' President and Chief Executive Officer, stated, "The momentum we built during the first quarter continued in the second quarter.
  • Second quarter sales and other operating revenues grew by 22.8% to $624.3 million, an increase of $116.0 million over the second quarter of fiscal 2023.
  • Pyxus achieved a gross margin of 14.2% of revenues, which represents a full percentage point of increased profitability over the year-ago second quarter.
  • The Company increased second quarter operating income to $46.3 million as compared to $27.1 million in the prior year's second quarter.

Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 6, 2023
PCV, FDA, Genetically modified bacteria, IND, Ageing, Food, Biologics license application, Immunization, Advisory Committee on Immunization Practices, Second Half, IPD, CMC, G&A, Net, Research and development, Stage 2, Regulation of tobacco by the U.S. Food and Drug Administration, Investment, R, Infant, Licensure, Data monitoring committee, Growth, Advisory Committee, General Administration of Sport of China, Success, Safety, Administration, BLA, SAN, Pharmaceutical industry, Vaccine, Cryptocurrency, Fine chemical

-- $1.4 Billion in Cash, Cash Equivalents and Investments as of September 30, 2023 --

Key Points: 
  • Initiation of the Phase 1/2 study in the fourth quarter of 2023.
  • Cash Position: Cash, cash equivalents and investments were $1,434.2 million as of September 30, 2023, compared to $957.9 million as of December 31, 2022.
  • The increase was due primarily to higher personnel-related expenses related to the growth in G&A employees as the Company continues to scale.
  • Net Loss: For the three months ended September 30, 2023, net loss was $92.7 million, compared to $57.9 million for the same period in 2022.

Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update

Retrieved on: 
Thursday, November 2, 2023
Research, Society for Hematology and Stem Cells, PIN, Second Half, PFS, Investment, News, SITC, Annual general meeting, Kinetics, ICML, Infection, CAR, International Conference on Afghanistan, London (2010), CD70, Society for Immunotherapy of Cancer, GAAP, Licensure, ORR, University, Cancer, Anti-CD19 immunotoxin, Therapy, Patient, Lymphoma, ASCO, B-cell lymphoma, Congress, Conference, Cytopenia, ASH, Immunotherapy, Dor, Cytokine release syndrome, Follicular lymphoma, Society, MD Anderson Cancer Center, Investigational New Drug, Kite Pharma, AACR, IND, Incidence, FC, American Society of Clinical Oncology, RCC, Poster, General counsel, Vaccine, Pharmaceutical industry

Following the close of the third quarter, the Company announced Geoffrey Parker as Executive Vice President, Chief Financial Officer, overseeing the Company’s financial operations and business development activities.

Key Points: 
  • Following the close of the third quarter, the Company announced Geoffrey Parker as Executive Vice President, Chief Financial Officer, overseeing the Company’s financial operations and business development activities.
  • Research and development expenses were $46.0 million for the third quarter of 2023, which includes $6.7 million of non-cash stock-based compensation expense.
  • General and administrative expenses were $17.0 million for the third quarter of 2023, which includes $8.6 million of non-cash stock-based compensation expense.
  • Allogene will host a live conference call and webcast today at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss financial results and provide a business update.

Hywin Holdings to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on November 8th 2023

Retrieved on: 
Wednesday, November 1, 2023
SEHK, ADR, Second Half, Greater China, Conference, Informatization, Electric Sugar Refining Company, HYW, Specialization, Cryptocurrency

This virtual investor conference is aimed exclusively at introducing global companies with ADR programs to investors.

Key Points: 
  • This virtual investor conference is aimed exclusively at introducing global companies with ADR programs to investors.
  • This will be a live, interactive online event where investors are invited to ask the company questions in real-time.
  • On September 15, 2023, Hywin reported solid financial results for the Second Half and Fiscal Year 2023 ended June 30, 2023.
  • On June 1, 2023, Hywin was named “Best Wealth Manager of Greater China 2023”.

CLPS Incorporation Reports Financial Results for the Second Half and Full Year of Fiscal 2023

Retrieved on: 
Wednesday, October 18, 2023
Research, Operating cost, RMB, Education, Tax, Fiscal, Second Half, Pressure, Federal Reserve, Talent, Acquisition, CLPS, Federal, Incorporation, Growth, COVID-19, Marketing, Clothing, Tourism, Cryptocurrency, Music, Renewable energy, Bank, Reinsurance, Health insurance, Fossil fuel, Security (finance), Video game

HONG KONG, Oct. 18, 2023 /PRNewswire/ -- CLPS Incorporation (the "Company" or "CLPS") (Nasdaq: CLPS), today announced its financial results for the six months ended June 30, 2023 and full year of fiscal 2023.

Key Points: 
  • HONG KONG, Oct. 18, 2023 /PRNewswire/ -- CLPS Incorporation (the "Company" or "CLPS") (Nasdaq: CLPS), today announced its financial results for the six months ended June 30, 2023 and full year of fiscal 2023.
  • Unaudited Second Half of Fiscal 2023 Highlights (all results compared to the six months ended June 30, 2022)
    Revenue from wealth management area increased by 9.2% to $18.6 million from $17.0 million.
  • In the second half of fiscal 2023, revenues decreased by $2.5 million, or 3.3%, to $73.6 million from $76.1 million in the prior year period.
  • Gross profit decreased by $2.7 million, or 14.2%, to $16.0 million in the second half of fiscal 2023, from $18.7 million in the prior year period.

Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Retrieved on: 
Wednesday, September 20, 2023
Orphan Drug Act of 1983, DYN, Therapy, DM1, Clinical trial, Plasma protein binding, Diagnosis, FDA, MPH, Second Half, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Dyne, Food, Safety, Pharmaceutical industry

WALTHAM, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for DYNE-101 for the treatment of myotonic dystrophy type 1 (DM1). DYNE-101 is being evaluated in the Phase 1/2 global ACHIEVE clinical trial with initial data on safety, tolerability and splicing from the multiple ascending dose, placebo-controlled portion of the trial anticipated in the second half of 2023.

Key Points: 
  • DYNE-101 is being evaluated in the Phase 1/2 global ACHIEVE clinical trial with initial data on safety, tolerability and splicing from the multiple ascending dose, placebo-controlled portion of the trial anticipated in the second half of 2023.
  • “Receiving FDA orphan drug designation for DYNE-101 underscores the importance of bringing new treatment options to people living with DM1, a rare, devastating disease with no approved therapies.
  • We believe DYNE-101 has the potential to be a transformative therapy which is why we designed the ACHIEVE trial to be registrational,” said Wildon Farwell, M.D., MPH, chief medical officer of Dyne.
  • Under the Orphan Drug Act, orphan drug designation qualifies a company for incentives, including tax credits, exemptions from certain FDA fees for clinical trials, and the potential for seven years of market exclusivity following drug approval.

Kamada Reports Strong Second Quarter and First Half 2023 Financial Results; Reiterates 2023 Revenue and Profitability Guidance

Retrieved on: 
Wednesday, August 16, 2023
Loss, International, Table, SDF, Eastern Time Zone, European Medicines Agency, Innova (video game company), G&A, KMDA, Action Replay, EMA, Internet, FIMI, EBITDA, Kamada, Acquisition, Investment, TASE, Immunoglobulin G, Depreciation, Growth, R, Adjustment, FDA, S&M, Second Half, Three Months, FEV1, Fiscal, Video game, Security (finance), Fine chemical, Pharmaceutical industry, Tutoring, Bookkeeping, Cryptocurrency

“Our strong start to 2023 continued in the second quarter, both financially and operationally,” said Amir London, Kamada’s Chief Executive Officer.

Key Points: 
  • “Our strong start to 2023 continued in the second quarter, both financially and operationally,” said Amir London, Kamada’s Chief Executive Officer.
  • Financial Highlights for the Three Months Ended June 30, 2023
    Total revenues were $37.4 million in the second quarter of 2023, a 59% increase from the $23.6 million recorded in the second quarter of 2022.
  • Gross profit and gross margins were $14.4 million and 39%, respectively, in the second quarter of 2023, compared to $7.2 million and 31%, respectively, reported in the second quarter of 2022.
  • Adjusted EBITDA, as detailed in the tables below, was $6.0 million in the second quarter of 2023, as compared to $1.3 million in the second quarter of 2022.

Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Monday, August 14, 2023
Friedreich's ataxia, DM1, Drug discovery, Clinical trial, Lead, G&A, Messenger, Excipient, Ongo, CTG, Patient, FXN, Design, DMPK, MAD, R, FA, Research, Therapy, Second Half, IND, Disease, D, Pharmaceutical industry

CARLSBAD, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today provided business updates and anticipated upcoming milestones across its clinical and research-stage pipeline of novel GeneTAC™ small molecules and reported second quarter 2023 financial results.

Key Points: 
  • CARLSBAD, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today provided business updates and anticipated upcoming milestones across its clinical and research-stage pipeline of novel GeneTAC™ small molecules and reported second quarter 2023 financial results.
  • With an expert team and strong financial position afforded by efficient cost and program management, I am confident in our ability to execute our goals.
  • The company plans to submit an IND for DT-168 in the second half of 2023.
  • Cash Position and Operating Runway: Cash, cash equivalents and marketable securities were $303.1 million as of June 30, 2023.